Zevra Therapeutics Inc (NASDAQ: ZVRA) is -3.48% lower on its value in year-to-date trading and has touched a low of $4.20 and a high of $9.76 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ZVRA stock was last observed hovering at around $7.93 in the last trading session, with the day’s gains setting it 0.12%.
Currently trading at $8.05, the stock is -3.25% and -7.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.22 million and changing 1.51% at the moment leaves the stock 18.59% off its SMA200. ZVRA registered 38.32% gain for a year compared to 6-month gain of 22.15%. The firm has a 50-day simple moving average (SMA 50) of $8.7066 and a 200-day simple moving average (SMA200) of $6.794075.
The stock witnessed a -4.62% loss in the last 1 month and extending the period to 3 months gives it a -4.85%, and is -0.74% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.59% over the week and 4.52% over the month.
Zevra Therapeutics Inc (ZVRA) has around 69 employees, a market worth around $429.68M and $24.79M in sales. Profit margin for the company is -342.63%. Distance from 52-week low is 91.67% and -17.52% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.75%).
with sales reaching $8.93M over the same period.The EPS is expected to shrink by -45.67% this year, but quarterly earnings will post -25.30% year-over-year. Quarterly sales are estimated to shrink -32.47% in year-over-year returns.
Zevra Therapeutics Inc (ZVRA) Top Institutional Holders
The shares outstanding are 53.23M, and float is at 53.08M with Short Float at 8.79%.
Zevra Therapeutics Inc (ZVRA) Insider Activity
The most recent transaction is an insider purchase by Watton Corey Michael, the company’s Director. SEC filings show that Watton Corey Michael bought 500 shares of the company’s common stock on Oct 11 ’24 at a price of $7.92 per share for a total of $3958.0. Following the purchase, the insider now owns 1500.0 shares.
Zevra Therapeutics Inc disclosed in a document filed with the SEC on Jul 17 ’24 that Clifton R. LaDuane (CFO & Treasurer) bought a total of 2,000 shares of the company’s common stock. The trade occurred on Jul 17 ’24 and was made at $6.77 per share for $13540.0. Following the transaction, the insider now directly holds 18469.0 shares of the ZVRA stock.
Still, SEC filings show that on Jul 16 ’24, Anderson Thomas (Director) acquired 10,000 shares at an average price of $6.81 for $68065.0. The insider now directly holds 20,000 shares of Zevra Therapeutics Inc (ZVRA).
